Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
2.110
+0.070 (3.43%)
At close: Nov 21, 2024, 4:00 PM
2.102
-0.008 (-0.39%)
After-hours: Nov 21, 2024, 5:46 PM EST
Immuneering Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | - | - | 0.32 | 2.08 | 2.31 | 1.92 |
| Revenue Growth (YoY) | - | - | -84.76% | -10.02% | 20.41% | - |
| Cost of Revenue | - | - | 0.16 | 1.15 | 1.28 | 1.22 |
| Gross Profit | - | - | 0.16 | 0.93 | 1.03 | 0.7 |
| Selling, General & Admin | 16.77 | 16.76 | 15.61 | 8.27 | 3.11 | 2.71 |
| Research & Development | 45.02 | 41.62 | 36.27 | 26.54 | 15 | 4.28 |
| Operating Expenses | 61.82 | 58.41 | 51.9 | 34.81 | 18.11 | 6.99 |
| Operating Income | -61.82 | -58.41 | -51.74 | -33.89 | -17.08 | -6.29 |
| Interest Expense | - | - | - | - | - | -0.35 |
| Interest & Investment Income | 2.93 | 3.61 | 1.01 | 0.17 | 0.04 | 0.06 |
| Other Non Operating Income (Expenses) | -0.2 | 0.32 | 0.05 | 0 | - | - |
| EBT Excluding Unusual Items | -59.09 | -54.49 | -50.68 | -33.71 | -17.04 | -6.58 |
| Gain (Loss) on Sale of Investments | 1.02 | 1.02 | 0.17 | -0.13 | - | - |
| Other Unusual Items | - | - | - | - | - | -1.12 |
| Pretax Income | -58.07 | -53.47 | -50.51 | -33.84 | -17.04 | -7.71 |
| Income Tax Expense | - | - | - | -0.31 | - | - |
| Net Income | -58.07 | -53.47 | -50.51 | -33.54 | -17.04 | -7.71 |
| Net Income to Common | -58.07 | -53.47 | -50.51 | -33.54 | -17.04 | -7.71 |
| Shares Outstanding (Basic) | 30 | 28 | 26 | 14 | 5 | 5 |
| Shares Outstanding (Diluted) | 30 | 28 | 26 | 14 | 5 | 5 |
| Shares Change (YoY) | 6.64% | 7.69% | 93.84% | 175.00% | -0.00% | - |
| EPS (Basic) | -1.97 | -1.88 | -1.91 | -2.46 | -3.44 | -1.56 |
| EPS (Diluted) | -1.97 | -1.88 | -1.91 | -2.46 | -3.44 | -1.56 |
| Free Cash Flow | -52.51 | -49.31 | -44.84 | -30.91 | -14.67 | -4.46 |
| Free Cash Flow Per Share | -1.78 | -1.74 | -1.70 | -2.27 | -2.96 | -0.90 |
| Gross Margin | - | - | 50.11% | 44.56% | 44.61% | 36.29% |
| Operating Margin | - | - | -16325.77% | -1629.17% | -739.01% | -327.71% |
| Profit Margin | - | - | -15937.29% | -1612.33% | -737.17% | -401.59% |
| Free Cash Flow Margin | - | - | -14148.44% | -1486.17% | -634.83% | -232.48% |
| EBITDA | -61.43 | -58.06 | -51.47 | -33.84 | -17.06 | -6.27 |
| D&A For EBITDA | 0.39 | 0.35 | 0.28 | 0.05 | 0.02 | 0.02 |
| EBIT | -61.82 | -58.41 | -51.74 | -33.89 | -17.08 | -6.29 |
Source: S&P Capital IQ. Standard template.
Financial Sources.